Checked
Surrozen, Inc.
Nasdaq: SRZN · Biological Products, (No Diagnostic Substances) · South San Francisco, CA
- Revenue
- $3.48M
- -67.4% vs. prior year
- Net income
- -$242M
- -6960.8% net margin
- Total assets
- $98.73M
- Diluted EPS
- -$32.37
Company details
As reported to the SEC
- SEC CIK
- 1824893
- Stock
- Nasdaq: SRZN
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) (2836)
- Headquarters
- 171 Oyster Point Blvd, Suite 400, South San Francisco, CA 94080
- Incorporated in
- Delaware
- Fiscal year end (SEC record)
- December 31
- Filer status
- Non-accelerated filer, Smaller reporting company
- Phone
- (650) 475-2820
- Employer ID (EIN)
- 30-1374889
- Last annual report
- 03/23/2026
- Last quarterly report
- 08/06/2026
Formerly: Consonance-HFW Acquisition Corp. (until 08/11/2021)
Annual financials
U.S. dollars, as tagged in each annual report's XBRL data. Later restatements replace earlier numbers. Select a date to open the filing.
| Fiscal year ended | 12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 |
|---|---|---|---|---|---|
| Revenue | $3.48M | $10.65M | $0 | $12.5M | $0 |
| Operating income | -$42.09M | -$25.54M | -$45.78M | -$44.34M | -$54.39M |
| Net income | -$242M | -$63.56M | -$43.04M | -$36M | -$54.65M |
| Diluted earnings per share | -$32.37 | -$21.67 | -$21.33 | -$15.56 | -$2.21 |
| Research and development | $29.36M | $21.13M | $27.23M | $37.01M | $40.18M |
| Total assets | $98.73M | $48.47M | $46.08M | $89.44M | $137.2M |
| Total liabilities | $286.5M | $69.85M | $8.14M | $13.43M | $27.47M |
| Shareholders' equity | -$187.8M | -$21.38M | $37.94M | $76M | $109.7M |
| Cash and cash equivalents | $89.25M | $34.56M | $36.04M | $24.69M | $33.09M |
| Cash from operations | -$30.24M | -$17.63M | -$40.36M | -$44.15M | -$48.81M |
| Capital expenditures | $128K | $26K | $398K | $728K | $1.27M |
Recent filings
106 recent filings on record; insider ownership forms (3, 4, 5 and 144) are not listed here
Swipe the table sideways to see more columns.
44 insider ownership reports (Forms 3, 4, 5 and 144) were filed about Surrozen, Inc. in the last 12 months. They list trades by officers, directors and large holders; see them on SEC EDGAR.
Other biological products, (no diagnostic substances)
Swipe the table sideways to see more columns.
| Company | Headquarters | Revenue | Net income |
|---|---|---|---|
| Amgen IncAMGN | Thousand Oaks, CA | $36.75B | $7.71B |
| Gilead Sciences, Inc.GILD | Foster City, CA | $29.44B | $8.51B |
| Biogen Inc.BIIB | Cambridge, MA | $9.89B | $1.29B |
| Neurocrine Biosciences IncNBIX | San Diego, CA | $2.86B | $478.6M |
| Exelixis, Inc.EXEL | Alameda, CA | $2.32B | $782.6M |
| Qiagen N.V.QGEN | Pl Venlo, Netherlands | $2.09B | $424.9M |
| Moderna, Inc.MRNA | Cambridge, MA | $1.94B | -$2.82B |
| Halozyme Therapeutics, Inc.HALO | San Diego, CA | $1.4B | $316.9M |
Profile refreshed Oct 26, 2026; financials refreshed Oct 22, 2026.
Frequently asked questions
- What is Surrozen, Inc.'s CIK number?
- Surrozen, Inc.'s SEC Central Index Key (CIK) is 1824893.
- What is Surrozen, Inc.'s stock ticker?
- Surrozen, Inc. trades as Nasdaq: SRZN.
- What was Surrozen, Inc.'s revenue?
- Surrozen, Inc. reported revenue of $3.48M for the fiscal year ended Dec 31, 2025, -67.4% from the year before.
- When does Surrozen, Inc.'s fiscal year end?
- Surrozen, Inc.'s fiscal year end on file with the SEC is December 31; its most recent fiscal year ended Dec 31, 2025.
- Where is Surrozen, Inc. headquartered?
- Surrozen, Inc.'s principal executive office on file with the SEC is in South San Francisco, CA.
Source: U.S. Securities and Exchange Commission, EDGAR submissions and XBRL company facts · Last updated 10/26/2026